This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BURKE, G. E. Articles by WRIGHT, I. S. Search for Related Content PubMed PubMed Citation Articles by BURKE, G. E. Articles by WRIGHT, I. S.

(Circulation. 1951;3:164.)
© 1951 American Heart Association, Inc.

---

Tromexan—3,3'-Carboxymethylenebis (4-Hydroxycoumarin) Ethyl Ester

Experimental and Clinical Properties

GRAFTON E. BURKE M.D.¹ IRVING S. WRIGHT M.D.¹

¹ From the Department of Medicine of Cornell University Medical College and The New York Hospital, New York.

The use of heparin and dicumarol has provided important information regarding the effectiveness and the difficulties of anticoagulant therapy. Neither, however, is an ideal anticoagulant; therefore a search for new substances with advantages over them must be continued. Tromexan, which is administered orally, appears to have the advantages of more rapid utilization and more rapid cessation of action than dicumarol, although the mode of action is similar in that it produces a hypoprothrombinemia. It does require accurate prothrombin tests for satisfactory clinical use. It appears to be less prone to producing hemorrhagic complications. Animal and clinical experiences with Tromexan are herewith presented.

This article has been cited by other articles:

				R. S. SCHAAF CARDIOVASCULAR DISEASES: A Review of Some Significant Publications (July 1949-June 1952) Arch Intern Med, February 1, 1954; 93(2): 254 - 298. [Abstract] [PDF]